tbuckley/cabot-search huggingface dataset:
Medical safety and side effects of methadone in tolerant individuals
Authors: M. J. Kreek
Journal: JAMA (1973)

In studies of patients having maintenance treatment for heroin addiction (stabilized with methadone hydrochloride in high doses of 80 to 120 mg daily), we found minimal side effects and no toxic effects. These studies have included a prospective study of the first consecutive 214 patients admitted to methadone treatment and reevaluation of the 129 patients of this group still in treatment after three or more years. In addition, we studied 1,435 methadone maintenance patients retrospectively and performed special studies on a smaller group. Abnormalities in liver function and serum protein tests, which were found in 57% and 49% of patients at admission, persisted without significant change during treatment. Increased sweating was reported by 48% and persistent constipation by 17% of patients after methadone treatment for three or more years.
Anisotropically Stiff 3D Micropillar Niche Induces Extraordinary Cell Alignment and Elongation
Authors: Yunus Alapan, Mousa Younesi, Ozan Akkus, Umut A. Gurkan
Journal: Advanced Healthcare Materials (2016)

A microfabricated pillar substrate is developed to confine, align, and elongate cells, allowing decoupled analysis of stiffness and directionality in 3D. Mesenchymal stem cells and cardiomyocytes are successfully confined in a 3D environment with precisely tunable stiffness anisotropy. It is discovered that anisotropically stiff micropillar substrates provide cellular confinement in 3D, aligning cells in the stiffer direction with extraordinary elongation.
Spotlight on measles 2010: Measles elimination in Europe – a new commitment to meet the goal by 2015
Authors: I Steffens, R Martin, P L Lopalco
Journal: Eurosurveillance (2010)

Preview this article: Spotlight on measles 2010: Measles elimination in Europe – a new commitment to meet the goal by 2015, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/50/art19749-en-1.gif
Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate
Authors: Aaron Kunamalla, Jason Ng, Vamsi Parini, Shin Yoo, Kate A. McGee, Todd T. Tomson, David Gordon, Edward B. Thorp, Jon Lomasney, Qiang Zhang, Sanjiv Shah, Suzanne Browne, Bradley P. Knight, Rod Passman, Jeffrey J. Goldberger, Gary Aistrup, Rishi Arora
Journal: Circulation Research (2016)

Fibrosis is an important structural contributor to formation of atrial fibrillation (AF) substrate in heart failure. Transforming growth factor-β (TGF-β) signaling is thought to be intricately involved in creation of atrial fibrosis.We hypothesized that gene-based expression of dominant-negative type II TGF-β receptor (TGF-β-RII-DN) in the posterior left atrium in a canine heart failure model will sufficiently attenuate fibrosis-induced changes in atrial conduction and restitution to decrease AF. Because AF electrograms are thought to reflect AF substrate, we further hypothesized that TGF-β-RII-DN would lead to increased fractionation and decreased organization of AF electrograms.Twenty-one dogs underwent injection+electroporation in the posterior left atrium of plasmid expressing a dominant-negative TGF-β type II receptor (pUBc-TGFβ-DN-RII; n=9) or control vector (pUBc-LacZ; n=12), followed by 3 to 4 weeks of right ventricular tachypacing (240 bpm). Compared with controls, dogs treated with pUBC-TGFβ-DN-RII demonstrated an attenuated increase in conduction inhomogeneity, flattening of restitution slope and decreased duration of induced AF, with AF electrograms being more fractionated and less organized in pUBc-TGFβ-DN-RII versus pUBc-LacZ dogs. Tissue analysis revealed a significant decrease in replacement/interstitial fibrosis, p-SMAD2/3 and p-ERK1/2.Targeted gene-based reduction of TGF-β signaling in the posterior left atrium-with resulting decrease in replacement fibrosis-led to beneficial remodeling of both conduction and restitution characteristics of the posterior left atrium, translating into a decrease in AF and increased complexity of AF electrograms. In addition to providing mechanistic insights, this data may have important diagnostic and therapeutic implications for AF.
Case 39-1964
Authors: Kenneth T. Bird, Benjamin Castleman
Journal: New England Journal of Medicine (1964)

Presentation of CaseA sixty-four-year-old woman was admitted to the hospital because of dyspnea.Thirty-one years previously she spent a year in a sanatorium, where repeated artificial pneumothorax was given in treatment of tuberculosis of the left lung. She was subsequently well, and periodic x-ray examinations of the chest showed no progression of the disease. Six years before admission exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, abdominal swelling and edema of the ankles developed. X-ray films of the chest taken at that time showed complete opacification of the left hemitho-rax, with marked shift of the heart and mediastinum into the left . . .
Abstract P2-13-05: A head to head comparison between SurgiMend® - Fetal bovine acellular dermal matrix and Epiflex® - Decellularized human skin tissue in breast reconstruction in 127 cases
Authors: C Eichler, N Vogt, K Brunnert, A Sauerwald, J Puppe, M Warm
Journal: Cancer Research (2016)

Abstract Introduction: The use of acellular dermal matrices (ADM) has become a widely used option in breast reconstruction. A great deal of literature is available, totaling over 2400 ADM reconstructions. Nonetheless, head to head comparisons between SurgiMend® and Epiflex® are not yet reported. In fact, this is the first clinical data report on the use of Epiflex®. This work will therefore compare postoperative complication rates and costs for these ADMs. Methods: This analysis is a retrospective review of a single surgeon's 6-year experience with both SurgiMend® – an acellular bovine dermal collagen matrix for soft-tissue reconstruction and Epiflex® – a decellularized human skin tissue from 2008 to 2013. Results: One hundred patients had a total of 127 implant based reconstructions using SurgiMend® (64 cases; 50.4 %) or Epiflex® (63 cases; 49.6%). Gross complication rates were 11.1 % for SurgiMend® and 40.6 % for Epiflex® including hematoma, postoperative skin irritation, infection, necrosis and revision surgery. The most common complication was postoperative red breast syndrome . Severe complications requiring revision surgery were significantly increased in patients treated with Epiflex® (12.5 %) compared to SurgiMend® (4.8 %). Conclusions: This retrospective analysis favors the use of SurgiMend® over Epiflex® due to significantly lower gross complication rates. Severe complication rates are comparable to those reported in literature for both products. Although results promote the use of SurgiMend®, the single surgeon, retrospective nature of this work limits its clinical impact. Citation Format: Eichler C, Vogt N, Brunnert K, Sauerwald A, Puppe J, Warm M. A head to head comparison between SurgiMend® - Fetal bovine acellular dermal matrix and Epiflex® - Decellularized human skin tissue in breast reconstruction in 127 cases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-13-05.
Potential role of asymptomatic kitchen food handlers during a food-borne outbreak of norovirus infection, Dublin, Ireland, March 2009
Authors: N Nicolay, R McDermott, M Kelly, M Gorby, T Prendergast, G Tuite, S Coughlan, P McKeown, G Sayers
Journal: Eurosurveillance (2011)

Binary file ES_Abstracts_Final_ECDC.txt matches
<i>A Rock on the Lukenia Hills</i>
Authors: Jeanette M. Smith
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
252. Using Cre-Dependent In Vivo Selection to Identify AAV Variants That Enable Efficient and Widespread Gene Transfer to the Adult Central Nervous System
Authors: Benjamin E. Deverman, Piers L. Pravdo, Bryan P. Simpson, Sripriya Ravindra Kumar, Yicheng Luo, Ken Y. Chan, Abhik Banerjee, Wei-Li Wu, Bin Yang, Nina Huber, Sergiu P. Pasca, Viviana Gradinaru
Journal: Molecular Therapy (2016)

Recombinant adeno-associated viruses (rAAVs) are commonly used vehicles for in vivo gene transfer. However, the tropism repertoire of naturally occurring AAVs is limited, prompting the development of novel AAV capsids with more desirable transduction characteristics. We have developed a capsid selection method, called Cre-recombination-based AAV targeted evolution (CREATE), that enables the identification of AAV capsids that more efficiently transduce defined cell populations in vivo (Deverman et al. in press, Nature Biotechnology). We generated AAV capsid libraries and used CREATE to identify variants that cross the blood brain barrier and efficiently and widely transduce astrocytes in the mouse central nervous system (CNS) after intravenous injection. One variant, AAV-PHPB, transfers genes throughout the adult CNS with an efficiency that is 40- to 92-fold greater (depending on the CNS region) than that of the current standard, AAV9. It transduces the majority of astrocytes and neurons across multiple CNS regions, and in vitro, it transduces human neurons and astrocytes more efficiently than does AAV9. We are now evolving AAV-PHP.B for even greater transduction of specific CNS cell types as a means to both develop more effective vectors and to gain insight into the mechanism of enhanced transduction. Our identification of AAV-PHP.B and several other enhanced vectors after only two rounds of selection establishes CREATE as a powerful method to customize AAV vectors for biomedical applications.
Abstract IA16: Clonal evolution in breast cancer patients and patient derived xenografts
Authors: Samuel Aparicio
Journal: Cancer Research (2016)

Abstract The notion that most cancers are ecosystems of evolving clones has implications for biological understanding and clinical application. The evolution of clonal composition has particular significance when evidence of positive or negative selection can be associated with the clonal genotype or epigenotype. Over the last 4 years next generation sequencing of tumors and methods for single cell analysis have opened up this approach for solid epithelial malignancies. I will discuss the implications of clonal evolution for cancer medicine and biological studies of cancer with reference to breast cancers. We have developed informatics approaches to population level clonal analysis and extended these to single cell measurements of genotypes. I shall discuss our more recent data from single cell sequencing and clonal analysis applied to clonal evolution of patient derived tumor xenografts, to illustrate the impact of clonal evolution on biological studies of cancer in model systems. Citation Format: Samuel Aparicio. Clonal evolution in breast cancer patients and patient derived xenografts. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA16.
Abstract A07: Long noncoding RNA PANCRNA1 is a novel regulator of cell growth and motility in pancreatic ductal adenocarcinoma
Authors: Husna Karaboga, Philip Jonsson, Yu Liu, Chin-Yo Lin
Journal: Cancer Research (2016)

Abstract Recent advances in sequencing technology have been increasing our understanding of non-protein coding regions in the mammalian genome. There is growing recognition that the majority of mammalian genome produces long non-coding RNA (lncRNA). Generally, their expression is lower than protein-coding genes and they are strikingly tissue-specific. Several studies have shown that they function in various aspects of cell biology. Abnormal expression and dysregulation of lncRNAs are associated with various types of cancer including pancreatic ductal adenocarcinoma (PDAC), which has the worst prognosis of the major cancers, with a 5-year survival rate of 5%, due to difficulties in early detection and limited therapeutic options. Although lncRNAs play important roles in cancer, they have not been extensively studied in PDAC. The goal of this study is to identify PDAC-related lncRNAs and characterize their functions in pancreatic cancer cells. Recently, we identified a potentially important lncRNA, PANCRNA1 (pancreatic cancer RNA 1), in PDAC progression through re-annotation of whole genome transcript RNA sequencing data of PDAC tissue samples from sequence read archive (SRA). Overexpressed candidates were determined in both early stage and metastatic PDAC tissue samples. PANCRNA1 shows a statistically significant higher expression profile in PDAC tissue samples. Its expression in different pancreatic cancer cell lines was confirmed (BxPC-3, MiaPaca-2 and Panc-1) by RT-qPCR. In order to investigate the effect of PANCRNA1 on pancreatic cancer cells, its expression was transiently knocked down using targeting siRNA. Statistically significant changes were reported on cell phenotype by measuring the rate of cell proliferation and motility. PANCRNA1 knock down reduced proliferation and cell motility in wound healing assays as compared to scrambled siRNA controls. To determine potential mechanisms underlying the observed effects of PANCRNA1 on pancreatic cancer cells, changes in epidermal growth factor receptor (EGFR) signaling, which contributes to pancreatic tumor cell proliferation, evasion of apoptosis, angiogenesis and metastasis were investigated. Knock down of PANCRNA1, decreased both EGFR transcript and protein levels. These results provide the first evidence for the expression and the function of PANCRNA1 in pancreatic cancer and the motivation for future studies to further elucidate its mechanisms of action and determine its possible application as a marker and target. Citation Format: Husna Karaboga, Philip Jonsson, Yu Liu, Chin-Yo Lin. Long noncoding RNA PANCRNA1 is a novel regulator of cell growth and motility in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr A07.
Anxious and nonanxious depression
Authors: R T Joffe, R M Bagby, A Levitt
Journal: American Journal of Psychiatry (1993)

The authors used the anxiety summary score described by Clayton and associates to assess anxious and nonanxious subtypes of depression in a group of 134 outpatients with major depression. Patients with anxious depression were only slightly less likely to respond to their first tricyclic antidepressant than patients with nonanxious depression. When functional severity or symptom severity was controlled for, this differential treatment response did not hold.
Hybrid biliary interventions for Roux-en-Y anatomy
Authors: Jarek Kobiela, Stanislaw Hac
Journal: Endoscopy (2015)

We would like to congratulate Kedia et al. on their recent report describing the development of endoscopic retrograde cholangiopancreatography (ERCP) for Roux-en-Y anatomy (EDGE) [1]. The report described a two-stage procedure involving percutaneous endoscopic gastrostomy (PEG), followed by ERCP through the gastrostomy 3 – 9 days later. It is an invaluable contribution in an era of widespread bariatric surgery performed on relatively young patients, some of whom will certainly require biliary interventions at some point in the future. However, as surgeon endoscopists we cannot refrain from commenting on the evolving concept of minimally invasive techniques in this field.
Growth of Mouse Ascites Tumor Cells in Diffusion Chambers. II. Lysis and Growth Inhibition by Diffusible Isoantibody&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: D. Bernard Amos, June D. Wakefield
Journal: JNCI Journal of the National Cancer Institute (1959)

Isoantibody was injected into mice in which the DBA/2 lymphoma was growing rapidly inside sampling-type diffusion chambers. Many of the tumor cells were lysed within 4 hours, some recovery was evident by 24 hours, and the cell count inside the chamber increased rapidly within 48 hours. Lysis was roughly proportional to the amount of serum injected. Recovery of the tumor-cell population could be delayed, apparently indefinitely, by repeated injections of antiserum. Lysis or growth inhibition could be shown for several other ascites tumors including an Ehrlich clone and MC1M sarcoma. Two lymphomas, although lysed at high serum doses, appeared to have an accelerated rate of growth after injection of small volumes of antibody. When this acceleration was studied in greater detail, it was found that the rise in cell count followed a slight initial fall. Reasons for the failure of antibody to lyse all the tumor cells are not fully understood since the population may be completely destroyed in tests in vitro; the availability of complement appears to be a limiting factor.
Notes of Three Cases of Arsenical Poisoning
Authors: W. Whitford
Journal: BMJ (1884)

pvposal I expressed my own opinion very clearly on the contagium $~.clolra as far back as 1867, holding that wo had then no proof of the existence of a specific form of bacteria in cholera, but that the dis- ease depended on the introduction of.specific organic matter into tlhe i4tinaI canal.The Egyptian cholera, however, of 1883 will cer-: tdifily be 6onnected in the minds of scientific men with the admirable researches commenced by Dr. Koch into the micro-organisms of choleia This work Dr. Koch has subsequently carried on in Cal- cptta; and, although no one can receive his admirable reports witli peater satisfaction than I do, it is impossible to ignore the fact that this 'most important work is being effected in our Indian possessions, it, is true, by brethreni, but nevertheles by rivals.Dr, Koch has found bacteria in the walls, epithelium, 'and glands of the ijtes- tal, oanals of persons dying from cholera.He has separated and cul- tvatte_ these bacteria, and findls they differ from those dliscovere(d in paae$ of diarrhoea anid dysentery.The presence of these bacteria, Dr.Kochi ibeIieves, excites sufficient irritation in the mucous nmem- brane of the intestines to cause the symptomiis of cholera.But it is said that heaps of micro-organisms exist in the contents of the intes- tinal canal and in decaying epithelium in all, parts of the body; but this is Ino reason wlhy some form of specific bacteria may niot exist in ca,ses f cholera.We might as well say that no form of pus contains specific qualities because, under the mnicroscope, all pus looks very muctaliike.By its effects we know that pus (lifl'ers in its properties in a ,ery remarkable way.Then, again, it is said the micro-organisms are the effect of disease, not the cause.But how can disease produce a li,ving micro-organism ?If, on the otlher hand, yon fin(d the Imlucous nlembraie of the initestine perforated, and, in fact, its tissues swarm- ing with micro-orgailislmis, wlhich appear to be living at the expense of tjlcse structures, surely it is nlot difficult to imagine that we have in such organisms a sufficient cause of irritatioin to account for the sym- Ptbms of clholera.It is satisfactory, however, to tind that, while pro- seutiig hlis researclhes into the minicro-organiismis found in the walls of taie.iiitestinies in cases of clholera, Dr. Kochl has beeni ledl to ini- quV1ie into the cause of the remarkable diminutioni in the death-rate 'fib'mu cholera inl Calcutta sinlce the introduction of the niew water-supply intp itat city.In miiy work oIn the History of Cholera, published in 1876, p. 423, I have gone fully inito this subject, and the still more reBarkable instance ot' the conditioni of our troOps in Fort William.
Endpiece: Students at Guy's and St Thomas's, 1819
Authors: Jeremy Hugh Baron
Journal: BMJ (2004)

I must be permitted to caution you against blindly adopting any system of opinion and practice which may be taught in the schools to which you may be... attached; this could be to degrade you to the ranks of empiricism. Think for yourselves.

Aesculapius. The hospital pupil's guide at St Thomas's and Guy's Hospitals.

Lond Med Repository 1819;11: 128-30
Modern diagnosis schizophrenia in hospitalized psychiatric patients
Authors: R Ries, J Bokan, M A Schuckit
Journal: American Journal of Psychiatry (1980)

The authors applied modern criteria to the diagnosis of 254 patients admitted to the psychiatric wards of an urban hospital. They found that only 16 (6.3%) met the St. Louis criteria for schizophrenia. Other studies using similar criteria also reported a consistently low prevalence of schizophrenia in general psychiatric inpatient populations. However, 30 "undiagnosed" patients (12%) in this study narrowly missed the definite diagnosis of schizophrenia because of the presence of affective disorder and/or insufficient duration of symptoms. The authors discuss the clinical and research implications of these findings.